Retatrutide and Dysesthesia: Evidence Summary
Dysesthesia, including burning skin sensations, is an emerging adverse effect associated with retatrutide that appears to be dose-dependent and more common with higher-potency GLP-1 receptor agonists. 1
Key Clinical Findings
Incidence and Characteristics
Pharmacovigilance data mining from VigiBase reveals that dysesthesia represents a class effect across GLP-1 receptor agonists, with specific patterns emerging for different agents 1:
- Semaglutide: Significantly associated with dysesthesia, hyperaesthesia, and burning sensations
- Tirzepatide: Associated with hyperaesthesia
- Retatrutide: Clinical trial data confirms dysesthesia as an observed adverse effect 1
The burning skin sensation represents a distinctive form of dysesthesia that has been increasingly reported on social media platforms and medical forums, strengthening the signal observed in formal clinical trials. 1
Dose-Dependency Pattern
The evidence demonstrates that dysesthesia occurs more frequently:
- At higher doses of GLP-1 receptor agonists
- With more potent receptor agonists (retatrutide being a triple agonist would theoretically carry higher risk)
- Regardless of whether the medication is used for weight management or type 2 diabetes 1
Clinical Management
Natural History
- Discontinuation typically leads to spontaneous favorable outcomes 1
- Cases of successful rechallenge have been documented, though this should be approached cautiously 1
Monitoring Considerations
When prescribing retatrutide, be aware that:
- Dysesthesia may manifest as paresthesias, burning sensations, or hyperaesthesia
- Symptoms appear related to the mechanism of more potent GLP-1 receptor activation
- The effect is distinct from the paresthesias seen with topiramate (which are related to carbonic anhydrase inhibition) 2, 3
Safety Profile Context
In the TRANSCEND-T2D-1 trial 4, retatrutide demonstrated:
- Most frequent adverse events were mild-to-moderate gastrointestinal events
- Study discontinuation rates due to adverse events were only 2-5% (vs 0% placebo)
- No specific quantification of dysesthesia rates was provided in the primary publication
The overall adverse event profile remains consistent with GLP-1 agonist activity, with dysesthesia representing an additional consideration rather than a contraindication to use. 4
Clinical Pitfalls to Avoid
- Do not confuse this with diabetic neuropathy progression - the temporal relationship to drug initiation and dose escalation is key
- Do not dismiss patient reports of burning sensations - this is a legitimate pharmacovigilance signal strengthened by multiple data sources 1
- Consider dose reduction before complete discontinuation if dysesthesia develops, given the documented dose-dependency 1
The evidence base for retatrutide-associated dysesthesia comes primarily from pharmacovigilance data mining rather than prospective clinical trial reporting, but the signal is strengthened by consistency across the GLP-1 agonist class and correlation with drug potency 1.